336O - Survival patterns of acute lymphoblastic leukemia among adolescents and children in the USA

Date 19 December 2016
Event ESMO Asia 2016 Congress
Session Haematological malignancies
Topics Cancers in Adolescents and Young Adults (AYA)
Presenter Inas Fadhlullah
Citation Annals of Oncology (2016) 27 (suppl_9): ix104-ix111. 10.1093/annonc/mdw586
Authors I.O. Fadhlullah1, N.M. Elameen1, G.G. El Sehrawy2
  • 1Faculty Of Medicine, Suez Canal University, 41111 - Ismailia/EG
  • 2Rheumatology, Suez Canal University Teaching Hospital, 41111 - Ismailia/EG



Acute lymphoblastic leukemia (ALL) is a malignant disease in which normal hematopoietic cells of the bone marrow are replaced by the proliferating lymphoid precursors. ALL is considered the most common type of cancer in children worldwide. This study aims to assess different prognostic factors affecting 5-year survival rates of patients diagnosed with ALL in the SEER database.


Patients' data were obtained from SEER database. We selected cases by sex, race, age at diagnosis (from 2 to 19 years), immunophenotype, and utilization of radiation. We used Kaplan-Meier method to analyze relative 5-year survival rates of 8965 patients diagnosed with ALL between 1988 and 2007.


Out of 8965 patients diagnosed with ALL, who met our selection criteria, 57.5% were males, 82.9% were white, and 70.2% were children (aged between 2 to 9 years). A significant difference in relative 5-year survival rate was observed (p value < 0.001) in females which was 87% compared to males which was 83%. There was significant difference in relative 5-year survival rate (p value < 0.001) for white patients which was 85.2% compared to other races. Children showed a 5-year survival rate of 90.4% compared to adolescents' survival rate which was 71.2%, (p value


Female patients, white races, children, patients with B cell immunophenotype, or those who did not receive radiation have shown better relative 5-year survival rates. The relative 5-year survival rate of T cell immunophenotype improved with radiation.

Clinical trial indentification

Legal entity responsible for the study

Inas Omar Fadhlullah


Inas Omar Fadhlullah


All authors have declared no conflicts of interest.